Funding
Series B · Biotech

Congruence Therapeutics raises $39.5M Series B

Congruence Therapeutics raised $39.5 million in Series B financing announced in March.

Updated Oct 16, 2026By RoundOS Funding desk

Dimension, OrbiMed, Amplitude Ventures, Fonds de solidarité FTQ, Lumira Ventures, Investissement Québec, BDC Capital’s Thrive Venture Fund, Driehaus Capital Management and Silver Arc are among its backers.

The company develops small-molecule correctors for diseases caused by protein misfolding.

Funding history

Series B · This round$39.5M

Sources

  1. Congruence Therapeuticsprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related